Recent Finacing
Recent Raise
Spirea develops an ADC platform enabling high drug-to-antibody ratios and stable, customizable conjugates with diverse payloads and validated in vivo activity against solid tumor models.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Spirea.
